Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Harries

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.
Molecular Cancer Therapeutics|November 12, 2014
Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaKristina M Ilieva, Isabel Correa, Debra H Josephs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal MetastasisAmanda Fitzpatrick, Marjan Iravani, Adam Mills, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast CancerMelek Akay, Jennifer Glendenning, Holly Tovey, et al.
Oncoimmunology|October 10, 2015
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanomaPanagiotis Karagiannis, Federica Villanova, Debra H Josephs, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
The Lancet. Oncology|April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyPippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
Plos One|May 12, 2011
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodiesAmy E Gilbert, Panagiotis Karagiannis, Tihomir Dodev, et al.
Journal of Medicinal Chemistry|July 10, 2010
Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulatorSimon E Ward, Mark Harries, Laura Aldegheri, et al.
Journal of Medicinal Chemistry|December 7, 2010
Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulatorsSimon E Ward, Mark Harries, Laura Aldegheri, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|March 22, 2003
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphomaIan Chau, Mark Harries, David Cunningham, et al.
Molecular Cancer Therapeutics|November 12, 2014
Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaKristina M Ilieva, Isabel Correa, Debra H Josephs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal MetastasisAmanda Fitzpatrick, Marjan Iravani, Adam Mills, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2026
A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast CancerMelek Akay, Jennifer Glendenning, Holly Tovey, et al.
Oncoimmunology|October 10, 2015
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanomaPanagiotis Karagiannis, Federica Villanova, Debra H Josephs, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
The Lancet. Oncology|April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyPippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
Plos One|May 12, 2011
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodiesAmy E Gilbert, Panagiotis Karagiannis, Tihomir Dodev, et al.
Journal of Medicinal Chemistry|July 10, 2010
Discovery of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide, a novel clinical AMPA receptor positive modulatorSimon E Ward, Mark Harries, Laura Aldegheri, et al.
Journal of Medicinal Chemistry|December 7, 2010
Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulatorsSimon E Ward, Mark Harries, Laura Aldegheri, et al.
Pageof 6